B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKACA

MOLECULAR TARGET

protein kinase cAMP-activated catalytic subunit alpha

UniProt: P17612NCBI Gene: 556624 compounds

PRKACA (protein kinase cAMP-activated catalytic subunit alpha) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKACA

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1ponatinib4.2670
2midostaurin3.8546
3sb 2021903.6437
4baricitinib3.5634
5tae 6843.4330
6gf 1092033.4029
7bms 7776073.3728
8linifanib3.3327
9at 92833.0921
10lestaurtinib3.0420
11pf 037583093.0019
12ruboxistaurin2.9418
13r 4062.8316
14capivasertib2.7715
15gsk 6906932.6413
16ast 4872.5612
17balanol2.309
18hydroxyfasudil [Supplementary Concept]2.208
19y 399832.208
20enzastaurin2.087
21uprosertib1.956
22afuresertib1.795
23sar 407899 free base1.795
24Sphingosine0.691

About PRKACA as a Drug Target

PRKACA (protein kinase cAMP-activated catalytic subunit alpha) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented PRKACA interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKACA inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.